Shares trade below the 200-week moving average, leaving room for gains, while the DKK2.6 bn buyback injected buy flows and liquidity. Investor positioning shifts favorably when prices retrace to the mid-$50 range.

Robust roll-out of expanded Wegovy offerings, including a high-dose 7.2 mg injection, oral formulation and EU 48-hour temperature-flexible delivery, is fueling sustained GLP-1 volume leadership above 60%, while diversified launches in basal insulin, distribution partnerships and a DKK 15 billion buyback underline strong execution, cash flow and moderate revenue growth targets.

Patent expirations in major markets and a Most Favoured Nations pricing agreement are triggering the launch of cheap semaglutide generics in regions like India, leading to rapid price cuts and market share shifts. Regulatory approvals for the Wegovy oral pill, once-weekly basal insulin and updated product specifications are expanding pharmacy, telehealth and subscription channels to simplify delivery and reduce costs. Potential tariffs for firms outside administrative agreements and Eli Lilly’s Foundayo pill introduction add further pricing and reimbursement complexity for GLP-1 treatments.

Investor sentiment remains buoyant on Wegovy pill momentum, expanded subscription and pricing models, and a deepening obesity pipeline, while growing caution surrounds near-term guidance cuts, discounting pressure and intensifying competition from Eli Lilly.

Announced repurchase targets bought back shares in a stock down 48% last year and ~26% YTD, generating only a modest intraday uptick under 5% versus HIMS’s 41–44% surge.

Global ramp in production for oral and injectable GLP-1 therapies is supported by a €432 million facility expansion in Ireland and partnerships with telehealth providers, driving 10% obesity and diabetes sales growth and a consensus revenue outlook of about $11.2 billion while launching Wegovy HD, oral semaglutide, and once-weekly basal insulin to meet rising patient demand.

Semaglutide patents are expiring in key markets like India, triggering a surge of low-cost generics and steep price competition. Novo Nordisk has responded with price cuts of up to 48%, subscription pricing models, and deals trading FDA priority review vouchers for tariff relief. Regulatory headwinds include FDA warning letters over safety-reporting and advertising claims, as well as potential broader U.S. drug-pricing negotiations under MFN and Medicare programs. Concurrently, capacity expansions and partnerships are underway to secure supply for oral GLP-1 production.

Enthusiasm over expanded access through partnerships with telehealth platforms, subscription-based pricing and new oral GLP-1 launches and trial readouts is countered by deep skepticism as investors digest slashed guidance, FDA warning letters, intensifying competition from Eli Lilly and looming patent expirations that frame recent weakness as signs of fundamental strain rather than a simple valuation reset.

Shares plunged by up to 20% intraday on head-to-head trial disappointment, driving the 14-day RSI below 19 and erasing nearly 40% of YTD gains, before a DKK533.8 million buyback and legal-action news sparked a roughly 7% rebound amid ongoing executive share sales.

2025 revenue rose 10% with operating profit up 6%, led by GLP-1 franchises and obesity care that expanded from DKK 6 billion in 2019 to DKK 82 billion in 2025 and Wegovy net sales up 36%. Fourth-quarter revenues of $12.34 billion fell 2% at constant currency amid slower Diabetes & Obesity sales and lower realized prices. Management foresees a 5–13% CER decline in sales and operating profit for 2026 as a transition year, while advancing oral semaglutide, next-generation candidates like CagriSema, and a $2.1 billion Vivtex delivery-platform partnership. The company is deploying aggressive cost discipline, investing in R&D, and returning cash via a DKK 52 billion dividend and DKK 15 billion share buyback.

Patent enforcement actions and FDA scrutiny are curbing compounded copycats while U.S. government price negotiations and MFN agreements are driving 35%–50% list-price cuts for semaglutide therapies; looming patent expirations, rising generic launches in key markets, and intensified head-to-head rivalry from rival oral and injectable GLP-1 developers are reshaping access, pricing and competitive barriers in obesity and diabetes treatment.

Investor sentiment soured after 2026 sales guidance was cut and late-stage trial data fell short, triggering disappointment and sharp sell-offs, while a smaller group points to the new oral GLP-1 pill, pipeline progress and valuation discounts as reasons for cautious optimism.